Treatment

Mean mRNA Expression
(Mean ratio of treated over controla)

CYP1A2

CYP2B6

CYP3A4

1 mM Remogliflozin

1.1 ± 0.16

1.0 ± 0.057

0.84 ± 0.19

10 mM Remogliflozin

1.7 ± 1.4

1.4 ± 0.18

1.7 ± 0.26

100 mM Remogliflozin

1.6 ± 0.38

2.2 ± 0.72

5.0 ± 2.4

Prototypical Inducerb

110 ± 83

8.6 ± 1.2 (PB) 14 ± 2.8 (Rif)

 50 ± 32

aControls are defined as 0.1% (v/v) DMSO; Values are expressed as a mean ± standard deviation of 3 human hepatocyte preparations. The criterion for notable induction is a response by the test compound that is greater than 20% of the response seen by the prototypical inducer bPrototypical CYP Inducers include: 50 μM Omeprazole for CYP1A2; 200 μM Phenobarbital (PB) for CYP2B6; 50 μM Rifampicin (Rif) for CYP3A4 and CYP2B6
Table 4: Induction of Cytochrome P450 mRNA by Remogliflozin in Human Hepatocytes.